Latest Articles
- ArticleSlowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease ProgressionPaolo Preziosa, Elisabetta Pagani, Alessandro Meani, et al.February 01, 2022
- ArticleBaicalin Promotes CNS Remyelination via PPARγ Signal PathwayRuo-Song Ai, Kun Xing, Xin Deng, et al.February 01, 2022
- ArticleHumoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple SclerosisAna Zabalza, Georgina Arrambide, Paula Tagliani, et al.February 01, 2022
- ArticleCortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 EncephalitisEero Rissanen, Kelsey Carter, Steven Cicero, et al.January 28, 2022
- ArticleOptic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal LossMickael Denis, Jean-Philippe Woillez, Vasily M. Smirnov, et al.January 28, 2022
- ArticleProgranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1/Th17 Cells and Promoting Treg Cells and M2 MacrophagesChaokui Wang, Wenjun Zhou, Guannan Su, et al.January 26, 2022
- ArticleDimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis LesionsNicole Zinger, Gerald Ponath, Elizabeth Sweeney, et al.January 19, 2022
- ArticleRisk of Getting COVID-19 in People With Multiple SclerosisA Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.January 19, 2022
- Clinical/Scientific NoteSEZ6L2 Antibody–Associated Cerebellar Ataxia Responsive to Sequential ImmunotherapyAyla Mehdiyeva, Aki Hietaharju, Jussi SipiläJanuary 14, 2022
- ArticleAssessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple SclerosisFrom the MS-STAT Randomized Controlled TrialThomas E. Williams, Katherine P. Holdsworth, Jennifer M. Nicholas, et al.January 14, 2022
Pages
Advertisement